Global Analgesics Market Overview:
The latest report by IMARC Group, titled “Analgesics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028”, offers a comprehensive analysis of the industry, which comprises insights on the analgesics market analysis report. The report also includes competitor and regional analysis, and contemporary advancements in the market. The global analgesics market size reached US$ 51.8 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 67.4 Billion by 2028, exhibiting a growth rate (CAGR) of 4.3% during 2023-2028. Analgesics, or painkillers, are drugs that are generally prescribed to relieve pain. They are of three types: non-opioids, opioids, and compound analgesics. Commonly having no side effects, they are used for treating pain resulting from surgeries, inflammation, phantom aches, neuropathic conditions, and cancer treatments. Some of the commonly available analgesics are paracetamol, morphine and oxycodone.
Request to get the sample report: https://www.imarcgroup.com/analgesics-market/requestsample
Global Analgesics Market Trends:
The global analgesics market is primarily driven by the rising incidences of chronic disorders, including arthritis, heart disease and cancer. Coupled with the growing geriatric population across the globe, there has been a considerable rise in the sales of analgesics. In line with this, the availability of well-established healthcare facilities and easy home deliveries by e-commerce platforms are also providing an impetus to the market growth. Apart from this, continual product innovations, the manufacturing of safer opioids with improved side effects, and continual research and development (R&D) activities conducted by key players are creating a positive outlook for the market.
Competitive Landscape with Key Players:
The market has also been examined with the presence of numerous small and large manufacturers who compete in terms of prices and quality. Some of the leading players are:
- Bayer AG
- Novartis International AG
- GlaxoSmithKline PLC
- Pfizer Inc.
- Johnson & Johnson Pvt. Ltd.
- Reckitt Benckiser (RB) Group PLC
- Endo Pharmaceuticals PLC
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Sanofi SA
Key Market Segmentation:
Type:
- Prescription
- Over the counter (OTC)
Drug Class:
- Opioids
- NSAID
- Others
Route of Administration:
- Oral
- Parenteral
- Topical
- Transdermal
- Rectal
Pain Type:
- Musculoskeletal
- Surgical and Trauma
- Cancer
- Neuropathic
- Migraine
- Obstetrical
- Fibromyalgia
- Pain due to Burns
- Dental/Facial
- Pediatric
- Others
Application:
- Internal
- External
Breakup by Region:
- North America (United States, Canada)
- Europe (Germany, France, United Kingdom, Italy, Spain, Others)
- Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)
On the geographical front, North America enjoys the leading position in the market. This can be attributed to the rising penetration of generics, coupled with the growing healthcare expenditure in the region.
Key highlights of the report:
- Market Performance
- Market Outlook
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape
Note: We are updating our reports, If you want latest primary and secondary data with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours.
Report Coverage:
Report Features | Details |
---|---|
Base Year of the Analysis | 2022 |
Historical Period | 2017-2022 |
Forecast Period | 2023-2028 |
Units | US$ Billion |
Segment Coverage | Type, Drug Class, Route of Administration, Pain Type, Application, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Companies Covered | Bayer AG, Novartis International AG, GlaxoSmithKline PLC, Pfizer Inc., Johnson & Johnson Pvt. Ltd., Reckitt Benckiser (RB) Group PLC, Endo Pharmaceuticals PLC, Bristol-Myers Squibb Company, Eli Lilly and Company and Sanofi SA |
Customization Scope | 10% Free Customization |
Report Price and Purchase Option | Single User License: US$ 2499 Five User License: US$ 3499 Corporate License: US$ 4499 |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Read More: https://techvizaca.com/